Literature DB >> 22738909

The MET oncogene is a functional marker of a glioblastoma stem cell subtype.

Francesca De Bacco1, Elena Casanova, Enzo Medico, Serena Pellegatta, Francesca Orzan, Raffaella Albano, Paolo Luraghi, Gigliola Reato, Antonio D'Ambrosio, Paola Porrati, Monica Patanè, Emanuela Maderna, Bianca Pollo, Paolo M Comoglio, Gaetano Finocchiaro, Carla Boccaccio.   

Abstract

The existence of treatment-resistant cancer stem cells contributes to the aggressive phenotype of glioblastoma. However, the molecular alterations that drive stem cell proliferation in these tumors remain unknown. In this study, we found that expression of the MET oncogene was associated with neurospheres expressing the gene signature of mesenchymal and proneural subtypes of glioblastoma. Met expression was almost absent from neurospheres expressing the signature of the classical subtype and was mutually exclusive with amplification and expression of the EGF receptor (EGFR) gene. Met-positive and Met-negative neurospheres displayed distinct growth factor requirements, differentiated along divergent pathways, and generated tumors with distinctive features. The Met(high) subpopulation within Met-pos neurospheres displayed clonogenic potential and long-term self-renewal ability in vitro and enhanced growth kinetics in vivo. In Met(high) cells, the Met ligand HGF further sustained proliferation, clonogenicity, expression of self-renewal markers, migration, and invasion in vitro. Together, our findings suggest that Met is a functional marker of glioblastoma stem cells and a candidate target for identification and therapy of a subset of glioblastomas. ©2012 AACR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22738909     DOI: 10.1158/0008-5472.CAN-11-3490

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  65 in total

Review 1.  Altered gene products involved in the malignant reprogramming of cancer stem/progenitor cells and multitargeted therapies.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Mol Aspects Med       Date:  2013-08-29

Review 2.  Molecular heterogeneity of glioblastoma and its clinical relevance.

Authors:  Katalin Eder; Bernadette Kalman
Journal:  Pathol Oncol Res       Date:  2014-08-27       Impact factor: 3.201

3.  Promise and challenges on the horizon of MET-targeted cancer therapeutics.

Authors:  Yu-Wen Zhang
Journal:  World J Biol Chem       Date:  2015-05-26

4.  MET signaling promotes DNA repair and radiation resistance in glioblastoma stem-like cells.

Authors:  Pavlina Krasimirova Todorova; Bipasha Mukherjee; Sandeep Burma
Journal:  Ann Transl Med       Date:  2017-02

5.  Targeted therapy by gene transfer of a monovalent antibody fragment against the Met oncogenic receptor.

Authors:  Elisa Vigna; Giovanni Pacchiana; Cristina Chiriaco; Simona Cignetto; Lara Fontani; Paolo Michieli; Paolo M Comoglio
Journal:  J Mol Med (Berl)       Date:  2013-09-07       Impact factor: 4.599

6.  Inhibition of EGFR induces a c-MET-driven stem cell population in glioblastoma.

Authors:  Hyun Jung Jun; Roderick T Bronson; Alain Charest
Journal:  Stem Cells       Date:  2014-02       Impact factor: 6.277

7.  Resetting cancer stem cell regulatory nodes upon MYC inhibition.

Authors:  Silvia Galardi; Mauro Savino; Fiorella Scagnoli; Serena Pellegatta; Federica Pisati; Federico Zambelli; Barbara Illi; Daniela Annibali; Sara Beji; Elisa Orecchini; Maria Adele Alberelli; Clara Apicella; Rosaria Anna Fontanella; Alessandro Michienzi; Gaetano Finocchiaro; Maria Giulia Farace; Giulio Pavesi; Silvia Anna Ciafrè; Sergio Nasi
Journal:  EMBO Rep       Date:  2016-11-16       Impact factor: 8.807

8.  Four individually druggable MET hotspots mediate HGF-driven tumor progression.

Authors:  Cristina Basilico; Anna Hultberg; Christophe Blanchetot; Natalie de Jonge; Els Festjens; Valérie Hanssens; Sjudry-Ilona Osepa; Gitte De Boeck; Alessia Mira; Manuela Cazzanti; Virginia Morello; Torsten Dreier; Michael Saunders; Hans de Haard; Paolo Michieli
Journal:  J Clin Invest       Date:  2014-05-27       Impact factor: 14.808

9.  Genome-wide methylomic and transcriptomic analyses identify subtype-specific epigenetic signatures commonly dysregulated in glioma stem cells and glioblastoma.

Authors:  Rajendra P Pangeni; Zhou Zhang; Angel A Alvarez; Xuechao Wan; Namratha Sastry; Songjian Lu; Taiping Shi; Tianzhi Huang; Charles X Lei; C David James; John A Kessler; Cameron W Brennan; Ichiro Nakano; Xinghua Lu; Bo Hu; Wei Zhang; Shi-Yuan Cheng
Journal:  Epigenetics       Date:  2018-08-06       Impact factor: 4.528

10.  Wnt/β-catenin signaling is a key downstream mediator of MET signaling in glioblastoma stem cells.

Authors:  Kang Ho Kim; Ho Jun Seol; Eun Hee Kim; Jinguen Rheey; Hyun Jin Jin; Yeri Lee; Kyeung Min Joo; Jeongwu Lee; Do-Hyun Nam
Journal:  Neuro Oncol       Date:  2012-12-20       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.